Short-term effects – vision remains unchanged
The researchers emphasize that these changes did not cause vision problems or other ailments. Participants with normal eyes maintained values within medically safe limits.
- However, a decrease in cell count of approximately 8% was considered a signal that required further monitoring, especially in people with existing eye diseases.
Who may be more at risk?
The recipe continues on the next page
According to the study, people who:
- have undergone eye surgery (e.g. cataract removal),
- had a corneal transplant,
- suffer from chronic eye diseases,
- already had decreased endothelial cell counts due to infection or inflammation.
For them, the additional decline may have greater clinical significance.
What’s next?
The researchers emphasize that the results should not be used in anti-vaccination narratives. The observations only cover a short period – two months after vaccination. Longer-term studies are needed to determine whether the changes persist and whether they may impact vision quality in the years to come.
Possible future consequences include decreased visual acuity, swelling or corneal clouding – especially in people already suffering from eye diseases.
Conclusions – there is no reason to panic
While the vaccine remains safe and healthy individuals have no cause for concern, researchers urge people with eye conditions to remain vigilant. If disturbing ophthalmological symptoms occur after vaccination, it is advisable to consult a doctor.
COVID-19 vaccines continue to play a crucial role in protecting public health. At the same time, the Turkish study shows that scientists should also closely monitor less obvious aspects of their effects, including their impact on vision.
